Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Explore which Aristocrats ETF is cheapest by examining expense ratios and trading costs across leading funds, helping you minimize fees and maximize returns.
19,765 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
A major offshore drilling reshuffle drives Transocean higher as Valaris merges with a multi‑billion agreement. This p...
Apple is leaning into a capital-light AI model that runs on-device and with trusted partners. This story explains why...
CFOs are increasingly moving into the CEO chair, but AI-driven disruption is testing how long they can stay. New data...
Palantir stock faces a pivotal moment as Aug. 3 earnings loom. This guide breaks down why a sharp rally could unfold,...
Tired of slow growth from buying one rental at a time? Discover how a portfolio approach can accelerate scale, maximi...
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
In 2026, the best real estate deals go to those who are proactive, data-driven, and connected. This guide shows rooki...
Conagra (CAG) faces a pivotal year as 2026 earnings hinge on pricing, cost control, and portfolio focus. This analysi...
A single week can rewrite crypto narratives. In this guide, we unpack the idea behind white whale week! lighter, what...
AT&T stunned investors with a record quarter, accelerating buybacks and signaling a robust cash flow backdrop. Here’s...
As shipping cycles turn, Safe Bulkers faces a critical earnings season. This guide deconstructs the Q4 2025 call, hig...